Ligand Pharmaceuticals Incorporated

NasdaqGM:LGND 株式レポート

時価総額:US$1.5b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Ligand Pharmaceuticals 配当金

配当金 基準チェック /06

Ligand Pharmaceuticals配当金を支払った記録がありません。

主要情報

n/a

配当利回り

n/a

配当性向

業界平均利回り2.2%
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
一株当たり利益US$5.36
3年後の配当利回り予想n/a

最近の配当金アップデート

更新なし

Recent updates

Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?

Jun 29
Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?

Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%

May 23
Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%

Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio

Apr 30

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar

Dec 19
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar

Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?

Jun 14
Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

May 29
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

May 07
Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

Jan 26
These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Oct 21
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Ligand Pharmaceuticals: Struggling Along

Sep 25

Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Aug 11
Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Jun 27
Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Ligand Pharmaceuticals: Moving Parts Keep Moving

Mar 29

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease

Mar 17
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease

Ligand: Green Shoots And A Hidden Treasure - A Spinoff Bonus For The New Year

Dec 31

決済の安定と成長

配当データの取得

安定した配当: LGNDの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: LGNDの配当金が増加しているかどうかを判断するにはデータが不十分です。


配当利回り対市場

Ligand Pharmaceuticals 配当利回り対市場
LGND 配当利回りは市場と比べてどうか?
セグメント配当利回り
会社 (LGND)n/a
市場下位25% (US)1.5%
市場トップ25% (US)4.7%
業界平均 (Pharmaceuticals)2.2%
3年後のアナリスト予想 (LGND)n/a

注目すべき配当: LGNDは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: LGNDは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。


株主への利益配当

収益カバレッジ: LGNDの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。


株主配当金

キャッシュフローカバレッジ: LGNDが配当金を報告していないため、配当金の持続可能性を計算できません。


高配当企業の発掘